CPT® Proprietary Laboratory Analyses (PLA) Codes: Long Descriptors

It is important to note that further CPT Editorial Panel (Panel) or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

Most recent changes to the CPT® Proprietary Laboratory Analyses (PLA) Long Descriptor document

- Revision of code 0090U, deletion of code 0208U, and the addition of 21 PLA codes (0285U-0305U) accepted by the CPT Editorial Panel.
- Deleted codes in this document appear with a ~~strikethrough~~.

Proprietary laboratory analyses (PLA) codes describe proprietary clinical laboratory analyses and can be either provided by a single ("sole-source") laboratory or licensed or marketed to multiple providing laboratories (eg, cleared or approved by the Food and Drug Administration [FDA]).

This subsection includes advanced diagnostic laboratory tests (ADLTs) and clinical diagnostic laboratory tests (CDLTs), as defined under the Protecting Access to Medicare Act (PAMA) of 2014. These analyses may include a range of medical laboratory tests including, but not limited to, multianalyte assays with algorithmic analyses (MAAA) and genomic sequencing procedures (GSP). The descriptor nomenclature follows, where possible, existing code conventions (eg, MAAA, GSP).

Unless specifically noted, even though the Proprietary Laboratory Analyses section of the code set is located at the end of the Pathology and Laboratory section of the code set, a PLA code does not fulfill Category I code criteria. PLA codes are not required to fulfill the Category I criteria. The standards for inclusion in the PLA section are:

- The test must be commercially available in the United States for use on human specimens and
- The clinical laboratory or manufacturer that offers the test must request the code.

For similar laboratory analyses that fulfill Category I criteria, see codes listed in the numeric 80000 series.

When a PLA code is available to report a given proprietary laboratory service, that PLA code takes precedence. The service should not be reported with any other CPT code(s) and other CPT code(s) should not be used to report services that may be reported with that specific PLA code. These codes encompass all analytical services required for the analysis (eg, cell lysis, nucleic acid stabilization, extraction, digestion, amplification, hybridization and detection). For molecular analyses, additional procedures that are required prior to cell lysis (eg, microdissection [codes 88380 and 88381]) may be reported separately.

►Codes in this subsection are released on a quarterly basis to expedite dissemination for reporting. PLA codes will be published electronically on the AMA CPT website (ama-assn.org/cpt-pla-codes), distributed via CPT data files on a quarterly basis, and, at a minimum, made available in print annually in the CPT codebook. Go to www.ama-assn.org/sites/default/files/media-browser/public/physicians/cpt/cpt-pla-codes-long.pdf for the most current listing. See the Introduction section of the CPT code set for a complete list of the dates of release and implementation.◄

All codes that are included in this section are also included in Appendix O, with the procedure's proprietary name. In order to report a PLA code, the analysis performed must fulfill the code descriptor and must be the test represented by the proprietary name listed in Appendix O. In some instances, the descriptor language of PLA codes may be identical and the code may only be differentiated by the listed proprietary name in Appendix O. When more than one PLA has an identical descriptor, the codes will be denoted by the symbol "♓."

Updated October 1, 2021

All PLA tests will have assigned codes in the PLA section of the code set. Any PLA coded test(s) that satisfies Category I criteria and has been accepted by the CPT Editorial Panel will be designated by the addition of the symbol "↑↓" to the existing PLA code and will remain in the PLA section of the code set.

If a proprietary test has already been accepted for a Category I code and a code has not been published, subsequent application for a PLA code will take precedence. The code will only be placed in the PLA section.

The accuracy of a PLA code is to be maintained by the original applicant, or the current owner of the test kit or laboratory performing the proprietary test.

►A new PLA code is required when:

1. Additional nucleic acid (DNA or RNA) and/or protein analysis(es) are added to the current PLA test, or
2. The name of the PLA test has changed in association with changes in test performance or test characteristics.

The addition or modification of the therapeutic applications of the test require submission of a code change application, but it may not require a new code number.◄

Proprietary Name and Clinical Laboratory and/or Manufacturer	Code	Long Code Descriptor	Released to AMA Website	Effective Date	Publication
UCompliDx, Elite Medical Laboratory Solutions, LLC, Elite Medical Laboratory Solutions, LLC (LDT)	▲0051U	Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrometry (LC-MS/MS), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service	**Revision Released to AMA Website** July 1, 2021	**Revision Effective** October 1, 2021	**Revision Publication** CPT® 2022
myPath® Melanoma, ~~Myriad Genetic Laboratories~~ Castle Biosciences, Inc	▲0090U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, ~~indeterminate~~ intermediate, malignant)	**Revision Released to AMA Website** October 1, 2021	**Revision Effective** January 1, 2022	**Revision Publication** CPT® 2023
~~BioFire® FilmArray® Respiratory Panel (RP) EZ, BioFire® Diagnostics~~	~~0098U~~	~~Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 14 targets (adenovirus, coronavirus, human metapneumovirus, influenza A, influenza A subtype H1, influenza A subtype H3, influenza A subtype H1-2009, influenza B, parainfluenza virus, human rhinovirus/ enterovirus, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae, Mycoplasma pneumoniae)~~	**Deletion Released to AMA Website** December 30, 2020	**Deletion Effective** April 1, 2021	**Deletion Publication** CPT® 2022

~~BioFire® FilmArray® Respiratory Panel (RP), BioFire® Diagnostics~~	~~0099U~~	~~Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 20 targets (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus, coronavirus OC43, human metapneumovirus, influenza A, influenza A subtype, influenza A subtype H3, influenza A subtype H1-2009, influenza, parainfluenza virus, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, human rhinovirus/enterovirus, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumonia, Mycoplasma pneumoniae)~~	**Deletion Released to AMA Website** December 30, 2020	**Deletion Effective** April 1, 2021	**Deletion Publication** CPT® 2022
~~BioFire® FilmArray® Respiratory Panel 2 (RP2), BioFire® Diagnostics~~	~~0100U~~	~~Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 21 targets (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus, human rhinovirus/enterovirus, influenza A, including subtypes H1, H1-2009, and H3, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, respiratory syncytial virus, Bordetella parapertussis [IS1001], Bordetella pertussis [ptxP], Chlamydia pneumoniae, Mycoplasma pneumoniae)~~	**Deletion Released to AMA Website** December 30, 2020	**Deletion Effective** April 1, 2021	**Deletion Publication** CPT® 2022
Lymph3Cx Lymphoma Molecular Subtyping Assay, Mayo Clinic, Laboratory Developed Test	0120U	Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter ►(Do not report 0120U in conjunction with 0017M)◄	**Parenthetical Note Posted to AMA Website** December 30, 2020	**Parenthetical Note Effective** January 1, 2021	**Parenthetical Note Publication** CPT® 2022
~~NPDX ASD Energy Metabolism, Stemina Biomarker Discovery, Inc, Stemina Biomarker Discovery, Inc~~	~~0139U~~	~~Neurology (autism spectrum disorder [ASD]), quantitative measurements of 6 central carbon metabolites (ie, α-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, and succinate), LC-MS/MS, plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)~~	**Deletion Released to AMA Website** July 1, 2021	**Deletion Effective** October 1, 2021	**Deletion Publication** CPT® 2022

Karius® Test, Karius Inc, Karius Inc	●▲0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, ~~PCR and~~ plasma, untargeted next-generation sequencing, ~~plasma, detection of >1,000 potential microbial organisms~~ report for significant positive pathogens	**Revision Posted to AMA Website** October 1, 2020	**Revision Effective** January 1, 2021	**Revision Publication** CPT® 2022
~~Vanadis® NIPT, PerkinElmer, Inc, PerkinElmer Genomics~~	~~0168U~~	~~Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma without fetal fraction cutoff, algorithm reported as a risk score for each trisomy~~	**Deletion Released to AMA Website** July 1, 2021	**Deletion Effective** October 1, 2021	**Deletion Publication** CPT® 2022
VeriMAP™ Peanut ~~Sensitivity~~ Reactivity Threshold - Bead Based Epitope Assay, AllerGenis™ Clinical Laboratory, AllerGenis™ LLC	0178U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction	**Revision of Test Name Posted to AMA Website** April 1, 2021	**Revision of Test Name Effective** July 1, 2021	**Revision of Test Name Publication** CPT® 2022
BioFire® Respiratory Panel 2.1 (RP2.1), BioFire® Diagnostics, BioFire® Diagnostics, LLC	~~+~~●0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected ►(For additional PLA code with identical clinical descriptor, see 0223U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)◄			**Duplicate PLA Symbol and Parenthetical Note Added to Publication** CPT® 2022
~~Afirma Medullary Thyroid Carcinoma (MTC) Classifier, Veracyte, Inc, Veracyte, Inc~~	~~0208U~~	~~Oncology (medullary thyroid carcinoma), mRNA, gene expression analysis of 108 genes, utilizing fine needle aspirate, algorithm reported as positive or negative for medullary thyroid carcinoma~~ ►(0208U has been deleted)◄	**Deletion Released to AMA Website** October 1, 2021	**Deletion Effective** January 1, 2022	**Deletion Publication** CPT® 2023
QIAstat-Dx Respiratory SARS CoV-2 Panel, QIAGEN Sciences, QIAGEN GmbH	~~+~~●0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	June 25, 2020	June 25, 2020	CPT® 2022

		▶(For additional PLA code with identical clinical descriptor, see 0202U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)◀			
COVID-19 Antibody Test, Mt Sinai, Mount Sinai Laboratory	●0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed ▶(Do not report 0224U in conjunction with 86769)◀	June 25, 2020	June 25, 2020	CPT® 2022
ePlex® Respiratory Pathogen Panel 2, GenMark Dx, GenMark Diagnostics, Inc	●0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	August 10, 2020	August 10, 2020	CPT® 2022
Tru-Immune™, Ethos Laboratories, GenScript® USA Inc	●0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), ELISA, plasma, serum	August 10, 2020	August 10, 2020	CPT® 2022
Comprehensive Screen, Aspenti Health	●0227U	Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation	October 1, 2020	January 1, 2021	CPT® 2022
PanGIA Prostate, Genetics Institute of America, Entopsis, LLC	●0228U	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer	October 1, 2020	January 1, 2021	CPT® 2022
Colvera®, ~~Colvera~~Clinical Genomics Pathology Inc	●0229U	*BCAT1 (Branched chain amino acid transaminase 1)* or *IKZF1 (IKAROS family zinc finger 1)* (eg, colorectal cancer) promoter methylation analysis	October 1, 2020	January 1, 2021	CPT® 2022

Genomic Unity® AR Analysis, Variantyx Inc, Variantyx Inc	●0230U	*AR (androgen receptor)* (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), full sequence analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions	October 1, 2020	January 1, 2021	CPT® 2022
Genomic Unity® CACNA1A Analysis, Variantyx Inc, Variantyx Inc	●0231U	*CACNA1A (calcium voltage-gated channel subunit alpha 1A)* (eg, spinocerebellar ataxia), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) gene expansions, mobile element insertions, and variants in non-uniquely mappable regions	October 1, 2020	January 1, 2021	CPT® 2022
Genomic Unity® CSTB Analysis, Variantyx Inc, Variantyx Inc	●0232U	*CSTB (cystatin B)* (eg, progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions	October 1, 2020	January 1, 2021	CPT® 2022
Genomic Unity® FXN Analysis, Variantyx Inc, Variantyx Inc	●0233U	*FXN (frataxin*) (eg, Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions	October 1, 2020	January 1, 2021	CPT® 2022
Genomic Unity® MECP2 Analysis, Variantyx Inc, Variantyx Inc	●0234U	*MECP2 (methyl CpG binding protein 2)* (eg, Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions	October 1, 2020	January 1, 2021	CPT® 2022
Genomic Unity® PTEN Analysis, Variantyx Inc, Variantyx Inc	●0235U	*PTEN (phosphatase and tensin homolog)* (eg, Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions	October 1, 2020	January 1, 2021	CPT® 2022

Genomic Unity® SMN1/2 Analysis, Variantyx Inc, Variantyx Inc	●0236U	*SMN1 (survival of motor neuron 1, telomeric)* and *SMN2 (survival of motor neuron 2, centromeric)* (eg, spinal muscular atrophy) full gene analysis, including small sequence changes in exonic and intronic regions, duplications, ~~and~~ deletions, and mobile element insertions	October 1, 2020	January 1, 2021	CPT® 2022
Genomic Unity® Cardiac Ion Channelopathies Analysis, Variantyx Inc, Variantyx Inc	●0237U	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including *ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2,* and *SCN5A,* including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions	October 1, 2020	January 1, 2021	CPT® 2022
Genomic Unity® Lynch Syndrome Analysis, Variantyx Inc, Variantyx Inc	●0238U	Oncology (Lynch syndrome), genomic DNA sequence analysis of *MLH1, MSH2, MSH6, PMS2,* and *EPCAM,* including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions	October 1, 2020	January 1, 2021	CPT® 2022
FoundationOne® Liquid CDx, ~~FOUNDATION MEDICINE, INC, FOUNDATION MEDICINE, INC~~ Foundation Medicine, Inc, Foundation Medicine, Inc	●0239U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations	October 1, 2020	January 1, 2021	CPT® 2022
Xpert® Xpress SARS-CoV-2/Flu/RSV (SARS-CoV-2 & Flu targets only), Cepheid	●0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	October 6, 2020	October 6, 2020	CPT® 2022
Xpert® Xpress SARS-CoV-2/Flu/RSV (all targets), Cepheid	●0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	October 6, 2020	October 6, 2020	CPT® 2022

Guardant360® CDx, Guardant Health Inc, Guardant Health Inc	●0242U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements	December 30, 2020	April 1, 2021	CPT® 2022
PlGF Preeclampsia Screen, PerkinElmer Genetics, PerkinElmer Genetics, Inc	●0243U	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia	December 30, 2020	April 1, 2021	CPT® 2022
Oncotype MAP™ Pan-Cancer Tissue Test, Paradigm Diagnostics, Inc, Paradigm Diagnostics, Inc	●0244U	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue	December 30, 2020	April 1, 2021	CPT® 2022
ThyGeNEXT® Thyroid Oncogene Panel, Interpace Diagnostics, Interpace Diagnostics	●0245U	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage	December 30, 2020	April 1, 2021	CPT® 2022
PrecisionBlood™, San Diego Blood Bank, San Diego Blood Bank	●0246U	Red blood cell antigen typing, DNA, genotyping of at least 16 blood groups with phenotype prediction of at least 51 red blood cell antigens	December 30, 2020	April 1, 2021	CPT® 2022
PreTRM®, Sera Prognostics, Sera Prognostics, Inc®	●0247U	Obstetrics (preterm birth), insulin-like growth factor–binding protein 4 (IBP4), sex hormone–binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth	December 30, 2020	April 1, 2021	CPT® 2022
3D Predict Glioma, KIYATEC®, Inc	●0248U	Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor-response prediction for each drug	April 1, 2021	July 1, 2021	CPT® 2022
Theralink® Reverse Phase Protein Array (RPPA), Theralink® Technologies, Inc, Theralink® Technologies, Inc	●0249U	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report	April 1, 2021	July 1, 2021	CPT® 2022

Updated October 1, 2021

PGDx elio™ tissue complete, Personal Genome Diagnostics, Inc, Personal Genome Diagnostics, Inc	●0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden	April 1, 2021	July 1, 2021	CPT® 2022
Intrinsic Hepcidin IDx™ Test, IntrinsicDx, Intrinsic LifeSciences™ LLC	●0251U	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma	April 1, 2021	July 1, 2021	CPT® 2022
POC (Products of Conception), Igenomix®, Igenomix® USA	●0252U	Fetal aneuploidy short tandem–repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy	April 1, 2021	July 1, 2021	CPT® 2022
ERA® (Endometrial Receptivity Analysis), Igenomix®, Igenomix® USA	●0253U	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)	April 1, 2021	July 1, 2021	CPT® 2022
SMART PGT-A (Pre-implantation Genetic Testing - Aneuploidy), Igenomix®, Igenomix® USA	●0254U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy, per embryo tested	April 1, 2021	July 1, 2021	CPT® 2022
Cap-Score™ Test, Androvia LifeSciences, Avantor Clinical Services (previously known as Therapak)	●0255U	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score	July 1, 2021	October 1, 2021	CPT® 2022
Trimethylamine (TMA) and TMA N-Oxide, Children's Hospital Colorado Laboratory	●0256U	Trimethylamine/trimethylamine N-oxide (TMA/TMAO) profile, tandem mass spectrometry (MS/MS), urine, with algorithmic analysis and interpretive report	July 1, 2021	October 1, 2021	CPT® 2022
Very-Long Chain Acyl-CoA Dehydrogenase (VLCAD) Enzyme Activity, Children's Hospital Colorado Laboratory	●0257U	Very long chain acyl-coenzyme A (CoA) dehydrogenase (VLCAD), leukocyte enzyme activity, whole blood	July 1, 2021	October 1, 2021	CPT® 2022

Mind.Px, Mindera, Mindera Corporation	●0258U	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics	July 1, 2021	October 1, 2021	CPT® 2022
GFR by NMR, Labtech™ Diagnostics	●0259U	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative	July 1, 2021	October 1, 2021	CPT® 2022
Augusta Optical Genome Mapping, Georgia Esoteric and Molecular (GEM) Laboratory, LLC, Bionano Genomics Inc	♓●0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping ►(For additional PLA code with identical clinical descriptor, see 0264U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)◄	July 1, 2021	October 1, 2021	CPT® 2022
Immunoscore®, HalioDx, HalioDx	●0261U	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score	July 1, 2021	October 1, 2021	CPT® 2022
OncoSignal 7 Pathway Signal, Protean BioDiagnostics, Philips Electronics Nederland BV	●0262U	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways *(ER, AR, PI3K, MAPK, HH, TGFB,* Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score	July 1, 2021	October 1, 2021	CPT® 2022
NPDX ASD and Central Carbon Energy Metabolism, Stemina Biomarker Discovery, Inc, Stemina Biomarker Discovery, Inc	●0263U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, α-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	July 1, 2021	October 1, 2021	CPT® 2022

Praxis Optical Genome Mapping, Praxis Genomics LLC	♓●0264U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping ►(For additional PLA code with identical clinical descriptor, see 0260U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)◄	July 1, 2021	October 1, 2021	CPT® 2022
Praxis Whole Genome Sequencing, Praxis Genomics LLC	●0265U	Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin-embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants	July 1, 2021	October 1, 2021	CPT® 2022
Praxis Transcriptome, Praxis Genomics LLC	●0266U	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes	July 1, 2021	October 1, 2021	CPT® 2022
Praxis Combined Whole Genome Sequencing and Optical Genome Mapping, Praxis Genomics LLC	●0267U	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ aHUS Genetic Evaluation, Versiti™ Diagnostic Laboratories, Versiti™	●0268U	Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Autosomal Dominant Thrombocytopenia Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0269U	Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Coagulation Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0270U	Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Congenital Neutropenia Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0271U	Hematology (congenital neutropenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022

Versiti™ Comprehensive Bleeding Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0272U	Hematology (genetic bleeding disorders), genomic sequence analysis of 51 genes, blood, buccal swab, or amniotic fluid, comprehensive	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Fibrinolytic Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0273U	Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of 8 genes *(F13A1, F13B, FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2, PLAU),* blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Comprehensive Platelet Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0274U	Hematology (genetic platelet disorders), genomic sequence analysis of 43 genes, blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Heparin-Induced Thrombocytopenia Evaluation – PEA, Versiti™ Diagnostic Laboratories, Versiti™	●0275U	Hematology (heparin-induced thrombocytopenia), platelet antibody reactivity by flow cytometry, serum	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Inherited Thrombocytopenia Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0276U	Hematology (inherited thrombocytopenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Platelet Function Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0277U	Hematology (genetic platelet function disorder), genomic sequence analysis of 31 genes, blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ Thrombosis Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0278U	Hematology (genetic thrombosis), genomic sequence analysis of 12 genes, blood, buccal swab, or amniotic fluid	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ VWF Collagen III Binding, Versiti™ Diagnostic Laboratories, Versiti™	●0279U	Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen III binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen III binding	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ VWF Collagen IV Binding, Versiti™ Diagnostic Laboratories, Versiti™	●0280U	Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen IV binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen IV binding	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ VWF Propeptide Antigen,	●0281U	Hematology (von Willebrand disease [VWD]), von Willebrand propeptide, enzyme-linked immunosorbent assays	July 1, 2021	October 1, 2021	CPT® 2022

Versiti™ Diagnostic Laboratories, Versiti™		(ELISA), plasma, diagnostic report of von Willebrand factor (VWF) propeptide antigen level			
Versiti™ Red Cell Genotyping Panel, Versiti™ Diagnostic Laboratories, Versiti™	●0282U	Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ VWD Type 2B Evaluation, Versiti™ Diagnostic Laboratories, Versiti™	●0283U	von Willebrand factor (VWF), type 2B, platelet-binding evaluation, radioimmunoassay, plasma	July 1, 2021	October 1, 2021	CPT® 2022
Versiti™ VWD Type 2N Binding, Versiti™ Diagnostic Laboratories, Versiti™	●0284U	von Willebrand factor (VWF), type 2N, factor VIII and VWF binding evaluation, enzyme-linked immunosorbent assays (ELISA), plasma	July 1, 2021	October 1, 2021	CPT® 2022
RadTox™ cfDNA test, DiaCarta Clinical Lab, DiaCarta Inc	●0285U	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score	October 1, 2021	January 1, 2022	CPT® 2023
CNT *(CEP72, TPMT* and *NUDT15)* genotyping panel, RPRD Diagnostics	●0286U	*CEP72 (centrosomal protein, 72-KDa)*, *NUDT15 (nudix hydrolase 15)* and *TPMT (thiopurine S-methyltransferase)* (eg, drug metabolism) gene analysis, common variants	October 1, 2021	January 1, 2022	CPT® 2023
ThyroSeq® CRC, CBLPath, Inc, University of Pittsburgh Medical Center	●0287U	Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)	October 1, 2021	January 1, 2022	CPT® 2023
DetermaRx™, Oncocyte Corporation	●0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes *(BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A)* and 3 reference genes (*ESD, TBP, YAP1)*, formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score	October 1, 2021	January 1, 2022	CPT® 2023
MindX Blood Test™ - Memory/Alzheimer's, MindX Sciences™ Laboratory, MindX Sciences™ Inc	●0289U	Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score	October 1, 2021	January 1, 2022	CPT® 2023
MindX Blood Test™ - Pain, MindX Sciences™ Laboratory, MindX Sciences™ Inc	●0290U	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score	October 1, 2021	January 1, 2022	CPT® 2023
MindX Blood Test™ - Mood, MindX	●0291U	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of	October 1, 2021	January 1, 2022	CPT® 2023

Sciences™ Laboratory, MindX Sciences™ Inc		144 genes, whole blood, algorithm reported as predictive risk score			
MindX Blood Test™ - Stress, MindX Sciences™ Laboratory, MindX Sciences™ Inc	●0292U	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score	October 1, 2021	January 1, 2022	CPT® 2023
MindX Blood Test™ - Suicidality, MindX Sciences™ Laboratory, MindX Sciences™ Inc	●0293U	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score	October 1, 2021	January 1, 2022	CPT® 2023
MindX Blood Test™ - Longevity, MindX Sciences™ Laboratory, MindX Sciences™ Inc	●0294U	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score	October 1, 2021	January 1, 2022	CPT® 2023
DCISionRT®, PreludeDx™, Prelude Corporation	●0295U	Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score	October 1, 2021	January 1, 2022	CPT® 2023
mRNA CancerDetect™, Viome Life Sciences, Inc, Viome Life Sciences, Inc	●0296U	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy	October 1, 2021	January 1, 2022	CPT® 2023
Praxis Somatic Whole Genome Sequencing, Praxis Genomics LLC	●0297U	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification	October 1, 2021	January 1, 2022	CPT® 2023
Praxis Somatic Transcriptome, Praxis Genomics LLC	●0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	October 1, 2021	January 1, 2022	CPT® 2023
Praxis Somatic Optical Genome Mapping, Praxis Genomics LLC	●0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	October 1, 2021	January 1, 2022	CPT® 2023

Praxis Somatic Combined Whole Genome Sequencing and Optical Genome Mapping, Praxis Genomics LLC	●0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	October 1, 2021	January 1, 2022	CPT® 2023
Bartonella ddPCR, Galaxy Diagnostics Inc	●0301U	Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR);	October 1, 2021	January 1, 2022	CPT® 2023
Bartonella Digital ePCR™, Galaxy Diagnostics Inc	●0302U	following liquid enrichment	October 1, 2021	January 1, 2022	CPT® 2023
Hypoxic BioChip Adhesion, BioChip Labs™, BioChip Labs™	●0303U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic	October 1, 2021	January 1, 2022	CPT® 2023
Normoxic BioChip Adhesion, BioChip Labs™, BioChip Labs™	●0304U	normoxic	October 1, 2021	January 1, 2022	CPT® 2023
Ektacytometry, BioChip Labs™, BioChip Labs™	●0305U	Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index	October 1, 2021	January 1, 2022	CPT® 2023